Intra-Cellular Therapies Inc. (ITCI)
| Market Cap | 3.38B |
| Revenue (ttm) | 37.61M |
| Net Income (ttm) | -232.34M |
| Shares Out | 80.95M |
| EPS (ttm) | -3.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $41.68 |
| Previous Close | $43.33 |
| Change ($) | -1.65 |
| Change (%) | -3.81% |
| Day's Open | 43.59 |
| Day's Range | 41.28 - 43.94 |
| Day's Volume | 695,063 |
| 52-Week Range | 17.26 - 43.94 |
Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 19.75% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 10.96% over the past year to ($0.65), which beat the esti...
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review ...
NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Webcast to be Held Tuesday, May 4, 2021 at 2:00 p.m. EDT
Board of Directors Nominates Sir Michael Rawlins GBE M.D., FRCP, FMedSci, Former Chairman of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), as a New, Independent Director Board of ...
Our research has demonstrated that the phosphodiesterase type 1 (PDE1) enzyme modulates the immune system by reducing macrophage and microglial activity with demonstrated effects in neuroinflammatory co...
Searching for drug developers that are innovative, but come with relatively low risk? Look no further.
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 10.59% and 0.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Successfully launched CAPLYTA ® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) expands its pipeline with a new molecular entity, ITI-1284, a sublingually delivered deuterated form of lumateperone. ITI-1284 has been developed in collabora...
ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particula...
Intra-Cellular Therapies Inc (NASDAQ: ITCI) submits CAPLYTA (lumateperone) supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder in adults. ...
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...
Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to previo...
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...
The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials.
After a magnificent performance last year with Caplyta approval for schizophrenia, Intra-Cellular stocks gave up some gains. And it's been trading in cyclical growth spurts of gives and takes. Investors...
These two biotech companies are safe bargains in today's volatile market.
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 17.71% and 12.97%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) remained unaffected after the company reported Q3 results.
P ositive topline results reported from Study ‘402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.
Innovation might be worth the high risk up front investment.
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nerv...
These companies show that specialization can be an excellent competitive strategy.
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...
The potential label expansion of lumateperone in bipolar depression could be a major breakthrough.
NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
Shares of a New York City biotechnology company shot up nearly 73% Wednesday, sparked by news that a drug it's testing could hit sales of more than $1 billion, earning it blockbuster status.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public off...
A nice bounce for the market was overdue.
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $350 mi...
Intra-Cellular Therapies (ITCI) is in the news Wednesday after announcing positive results from a recent study that sent ITCU stock soaring. The post Intra-Cellular Therapies News: Why ITCI Stock Is Sky...
Intra-Cellular Therapies on Wednesday revealed positive final-phase test results for a treatment for certain Bipolar I and Bipolar II disorders, sending ITCI stock soaring more than 70%. The post Positi...
Investors are reacting enthusiastically to the company's latest clinical results.
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) was one of the biggest winners on Wednesday after the company announced positive results from its late-stage clinical trial in patients with bipolar disorder.
Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food and...
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2020 Results - Earnings Call Transcript
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2020 Results - Earnings Call Transcript
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -2.13% and -37.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) fell 2% in pre-market trading after the company reported Q2 results.
Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central ne...
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without inducing...
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, t... [Read more...]
| Industry Biotechnology | |
| CEO Sharon Mates | Employees 383 |
| Stock Exchange NASDAQ | Ticker Symbol ITCI |
Financial Performance
In 2020, ITCI's revenue was $22.81 million, an increase of 37,537.11% compared to the previous year's $60,613. Losses were -$227.01 million, 53.7% more than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is 52.13, which is an increase of 25.07% from the latest price.